<DOC>
	<DOCNO>NCT00016900</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness PNU-93914 treating patient locally advanced metastatic cancer esophagus .</brief_summary>
	<brief_title>PNU-93914 Treating Patients With Locally Advanced Metastatic Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity duration activity PNU-93914 patient locally advance metastatic esophageal carcinoma . II . Determine objective tumor response rate tumor response duration patient treat drug . III . Determine survival patient treat drug . IV . Determine safety profile drug patient . V. Determine effect drug quality life patient . VI . Determine time tumor response , time tumor progression , time treatment failure patient treat drug . VII . Evaluate change dysphagia score patient treat drug . OUTLINE : This multicenter study . Patients receive PNU-93914 IV 60 minute day 1 . Treatment repeat every 21 day least 2 course absence disease progression unacceptable toxicity . Quality life assess baseline , day 1 course , final study visit . Patients follow every 3 month 2 year . PROJECTED ACCRUAL : A total 21-41 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell carcinoma adenocarcinoma esophagus Tumors gastroesophageal junction allow least 50 % tumor involve esophagus time initial diagnosis Locally advance metastatic disease amenable surgery radiotherapy curative intent Progressive disease 1 chemotherapy regimen locally advance metastatic disease Relapse within 6 month complete prior neoadjuvant chemotherapy allow Chemotherapy administer solely radiosensitizer consider prior chemotherapy regimen At least 1 nonirradiated measurable target lesion At least 20 mm least 1 dimension conventional technique OR At least 10 mm least 1 dimension spiral CT scan No known brain metastasis , spinal cord compression , carcinomatous meningitis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 2.5 time ULN ( 5 time ULN hepatic metastasis present ) Renal : Creatinine great 1.5 time ULN OR Creatinine clearance great 60 mL/min Cardiovascular : No myocardial infarction within past 6 month No unstable angina No New York Heart Association class III IV heart disease No severe uncontrolled cardiac arrhythmia Other : HIV negative No active infection No malignancy within past 5 year except curatively treat carcinoma situ cervix , ductal carcinoma situ breast , basal cell skin cancer , squamous cell carcinoma head neck within past 3 year No concurrent malignancy sit No psychiatric disorder would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent anticancer biologic response modifier immunotherapy No concurrent sargramostim ( GMCSF ) No concurrent prophylactic filgrastim ( GCSF ) first course study Chemotherapy : See Disease Characteristics Recovered prior chemotherapy No prior taxane therapy No concurrent anticancer chemotherapy Endocrine therapy : No concurrent anticancer hormonal therapy Radiotherapy : See Disease Characteristics Recovered prior radiotherapy Surgery : See Disease Characteristics Recovered prior surgery Other : At least 4 week since prior investigational agent No concurrent investigational therapy No concurrent participation clinical study No concurrent antitumor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>